12.30-1.30pm, Wed 14th March 2018
Seminar Room 515, Level 5, 207 Bouverie Street, Carlton
Professor Jonathan Sterne, Professor of Medical Statistics and Epidemiology, Department of Population Health Sciences, University of Bristol, UK; and Deputy Director, NIHR Bristol Biomedical Research Centre
The oral anticoagulant warfarin is effective for prevention of stroke in patients with atrial fibrillation. However, bleeding associated with warfarin is a major cause of hospitalisation, and warfarin treatment requires monitoring to ensure optimal efficacy while limiting the risk of bleeding. Direct acting (non-vitamin K antagonist) oral anticoagulants (DOACs) overcome some of the limitations of warfarin, offering important benefits that can improve quality of life for patients and their carers. The class includes factor II inhibitors (e.g. dabigatran) and factor Xa inhibitors (e.g. apixaban, betrixaban, edoxaban, and rivaroxaban). These are increasingly used in place of warfarin, based on randomized trials that have compared individual drugs with warfarin, but not with each other. Jonathan will describe the methods and results of a systematic review, network meta-analyses and cost-effectiveness analyses of 23 randomized trials that aimed to establish the optimal and most cost-effective treatment for patients with atrial fibrillation, and discuss limitations of the available evidence.
For more details, please view the Event Flyer.